Loading...
  • infusion
  • Evaluation of 3-hour infusion of paclitaxel plus cisplatin and 5-fluorouracil in patients with advanced/recurrent squamous cell carcinoma of the head and neck (SCCHN): Phase II (S0007). (wikipedia.org)
  • Treatment
  • Response rate (RECIST 1.1) will be determined as the proportion of evaluable patients who have complete response or partial response defined by the RECIST 1.1 within 32 weeks of treatment. (clinicaltrials.gov)
  • Three patients withdrew from the study before receiving treatment. (clinicaltrials.gov)
  • After completion of study treatment, patients are followed up for 1 year. (clinicaltrials.gov)
  • Clinical trial results have been published for treatment of acute myeloid leukemia, small cell lung cancer, Hodgkin's lymphoma, myelodysplastic syndromes, Teva halted a phase III trial in patients with lung cancer before it had begun, citing "business decisions" as the reason. (wikipedia.org)
  • Minimal residual disease (MRD) is the name given to small numbers of leukaemic cells (cancer cells from the bone marrow) that remain in the patient during treatment, or after treatment when the patient is in remission (no symptoms or signs of disease). (wikipedia.org)
  • Carfilzomib (marketed under the trade name Kyprolis) was approved by the FDA on June 20, 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy, and have demonstrated disease progression on or within 60 days of completion of the last therapy. (wikipedia.org)
  • disease
  • Tell patient to inform health care provider if diagnosed with any peripheral vascular disease. (drugs.com)
  • Patients with an uncontrolled medical disease such as uncontrolled diabetes, chronic renal (kidney) disease or active uncontrolled infection. (clinicaltrials.gov)
  • chronic myeloid
  • Patients with chronic myeloid leukemia, some other types of leukemias (abl-mutated) some types of gastrointestinal stromal tumours (c-KIT-positive), some systemic mastocytosis (if c-KIT D816V mutation), brain, prostate, breast or lung cancers. (clinicaltrials.gov)
  • response
  • I. To determine the response rate (complete and partial) to STI-571 in patients with myelofibrosis. (clinicaltrials.gov)
  • Response rate (RECIST 1.1) will be determined as the proportion of evaluable patients who have complete response or partial response defined by the RECIST 1.1 criteria with a one-sided 90% confidence interval (CI) and a two-sided 95% CI provided. (clinicaltrials.gov)
  • It will be determined as the proportion of patients who have complete response or partial response defined by the CHOI criteria with a two-sided 95% CI provided. (clinicaltrials.gov)
  • hypertensive
  • Since fenoldopam is the only intravenous agent that improves renal perfusion, in theory it could be beneficial in hypertensive patients with concomitant renal insufficiency. (wikipedia.org)
  • severe
  • when administered with ritonavir, in patients with severe hepatic impairment. (drugs.com)
  • Patients are stratified according to liver dysfunction (normal vs mild vs moderate vs severe). (clinicaltrials.gov)
  • While it is generally safe to use in patients with aortic stenosis (narrowing of the aorta where it meets the left ventricle) since it doesn't inhibit the ventricle's function, it can still cause collapse in cases of severe stenosis. (wikipedia.org)
  • Caution
  • Caution patient that this medication must not be taken during pregnancy or when pregnancy is possible. (drugs.com)
  • Fenoldopam mesylate administration should be undertaken with caution to patients with glaucoma or raised intraocular pressure as fenoldopam raises intraocular pressure. (wikipedia.org)
  • once
  • Patients who have relapsed once are at high risk of relapse in the future, and they may not respond as well to drugs they received in the past. (wikipedia.org)
  • symptoms
  • Fenoldopam mesylate contains sodium metabisulfite, a sulfite that may rarely cause allergic-type reactions including anaphylactic symptoms and asthma in susceptible people. (wikipedia.org)
  • least
  • In patients receiving bosentan, discontinue bosentan at least 36 h before starting saquinavir/ritonavir. (drugs.com)
  • people
  • When compared to people anticoagulated with warfarin, patients taking dabigatran had fewer life-threatening bleeds, fewer minor and major bleeds, including intracranial bleeds, but the rate of gastrointestinal bleeding was significantly higher. (wikipedia.org)
  • years
  • Patients were treated for a few weeks (rather than months or years as at present), producing remission, but nearly all patients relapsed after a few weeks or months. (wikipedia.org)
  • major
  • The use of dabigatran should also be avoided in patients with mechanical prosthetic heart valves due to the increased risk of thromboembolic events (e.g. valve thrombosis, stroke, and myocardial infarction) and major bleeding associated with dabigatran in this population. (wikipedia.org)